Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Elacestrant dihydrochloride (DA-DKRAD1901 dihydrochloride) 是一种具有口服活性的的选择性雌激素受体 (ER) 降解剂 (SERD),能够作用于 ERα (IC50:48 nM) 和 ERβ (IC50:870 nM)。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 925 | 现货 | ||
5 mg | ¥ 1,970 | 现货 | ||
10 mg | ¥ 3,260 | 现货 | ||
25 mg | ¥ 5,360 | 现货 | ||
50 mg | ¥ 7,550 | 现货 | ||
100 mg | ¥ 9,870 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,370 | 现货 |
产品描述 | Elacestrant dihydrochloride (DA-DKRAD1901 dihydrochloride) is an orally available selective estrogen receptor degrader with IC50s of 48 for ERα and 870 nM for ERβ, respectively. |
靶点活性 | ERβ:870 nM , ERα:48 nM |
体外活性 | Elacestrant exhibits inhibition of ERα expression in a dose-dependent manner, with an EC50 of 0.6 nM.?Treatment of ER-positive MCF-7 cells with E2 results in a potent and dose-dependent increase in proliferation, with an EC50 of 4 pM.?Treatment of cells with Elacestrant in the presence of 10 pM E2 results in a dose-dependent decrease in proliferation, with an IC50 value of 4.2 nM. Elacestrant selectively binds to and degrades the ER and is a potent antagonist of ER-positive breast cancer cell proliferation[1].? |
体内活性 | In MCF-7 xenograft models, Elacestrant-treated animals survived longer than those treated with either control or ICI 182780. RAD1901 preserves ovariectomy-induced bone loss and prevents the uterotropic effects of E2. Elacestrant produces a robust and profound inhibition of tumor growth in MCF-7 xenograft models[1].? |
别名 | RAD1901 dihydrochloride |
分子量 | 531.56 |
分子式 | C30H40Cl2N2O2 |
CAS No. | 1349723-93-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 80 mg/mL (150.50 mM), Sonication is recommended.
H2O: 40 mg/mL (75.25 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / H2O | 1 mM | 1.8813 mL | 9.4063 mL | 18.8126 mL | 47.0314 mL |
5 mM | 0.3763 mL | 1.8813 mL | 3.7625 mL | 9.4063 mL | |
10 mM | 0.1881 mL | 0.9406 mL | 1.8813 mL | 4.7031 mL | |
20 mM | 0.0941 mL | 0.4703 mL | 0.9406 mL | 2.3516 mL | |
50 mM | 0.0376 mL | 0.1881 mL | 0.3763 mL | 0.9406 mL | |
DMSO | 100 mM | 0.0188 mL | 0.0941 mL | 0.1881 mL | 0.4703 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Elacestrant dihydrochloride 1349723-93-8 Endocrinology/Hormones Estrogen/progestogen Receptor inhibit RAD-1901 Dihydrochloride Inhibitor Elacestrant Dihydrochloride RAD1901 Dihydrochloride Estrogen Receptor/ERR Elacestrant RAD 1901 Dihydrochloride RAD1901 RAD 1901 RAD-1901 RAD1901 dihydrochloride inhibitor